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Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are in common use worldwide. These drugs may sometimes be used in
high or toxic doses by mistake. In this study we investigated the effects of different doses of diclofenac sodium on liver and renal
tissues. Forty albino adult male Wistar rats weighing 200 to 220 g were divided equally into four groups. The rats in the control
group (n = 10) were each intramuscularly injected with 1 cc of physiologic saline. The other three groups were given diclofenac
sodium doses. The rats in the first (n = 10), second (n = 10) and third (n = 10) groups were intramuscularly injected with diclofenac
sodium at a low, medium and high dose of 50, 100 and 150 mg/kg live weight/day, respectively, every day for 5 days. At the end
of the experimental period (5 days), after the animals were sacrificed, they were autopsied and liver and kidney tissue samples were
prepared for histopathologic assessment.
No significant (P > 0.05) changes were observed in the histopathology of the liver or kidney tissues of the control rats. The
diclofenac sodium treatment significantly (P < 0.001) affected the histopathology of both the liver and kidney. Histopathologic
changes in the liver sections stained with hematoxylin and eosin in all diclofenac groups included claudy swelling and hydropic
degeneration of the liver cells, focal sinusoidal and vena centralis dilatation, proliferation of the bile duct in portal areas, enlargement
of the periportal area with mononuclear cell infiltration, hyperemia and dose-dependent fibrous tissues proliferation and focal
necrosis. Cloudy swelling and hydropic degeneration were seen in the tubular epithelial cells of the kidney tissue of all diclofenac
sodium treated groups. Necrosis, peritubular lymphocyte infiltration, stromal fibrous tissue proliferation and hyperemia were
observed in the second and third groups. In the liver and kidney tissue of the third group, which was given a high dose of diclofenac
sodium, necrosis, cloudy swelling and hydropic degeneration and inflammation were rather widespread and intensive, as compared
to the group given a low dose. The increase in fibrous tissue in the kidney and liver that caused irregularities in the periportal areas
was only seen in the group given a high dose. These results suggest that a high dose of diclofenac sodium causes meaningful changes
in liver and kidney tissue.
Key Words: Diclofenac sodium, liver, kidney, histopathologic changes

Farkl› Dozlarda Diclofenac Sodium’un Ratlar›n Karaci¤er ve Böbrek Dokusunda
Oluflturdu¤u Histopatolojik De¤ifliklikler
Özet: Non-steroidal anti-inflamatuar ilaçlar (NSAIDs) dünyada yayg›n olarak kullan›l›rlar. Bu ilaçlar bazen yaln›fll›kla yüksek ya da
toksik dozda kullan›labilirler. Bu çal›flmada, farkl› dozlarda diclofenac sodium’un karaci¤er ve böbrek dokular› üzerine etkilerini
araflt›rmay› amaçlad›k. Wistar Strain cinsi a¤›rl›klar› 200-220 gram olan 40 adet olgun Albino ratlar, her biri 10 rattan oluflan 4
gruba ayr›ld›. Kontrol grubu olan ratlara (n = 10) intramüsküler olarak 1 cc serum fizyolojik enjekte edildi. Di¤er üç gruba diclofenac
sodium’un farkl› dozlar› uyguland›. Birinci (n = 10), ikinci (n = 10) ve üçüncü (n = 10) grup ratlara 5 gün süre ile hergün 50, 100,
150 mg/kg, düflük, orta ve yüksek dozlarda diclofenac sodium intramüsküler olarak enjekte edildi. Befl günlük deney süresi sonunda
hayvanlar ötenazi edildikten sonra nekropsileri yap›larak, karaci¤er ve böbrek doku örnekleri histopatolojik inceleme için haz›rland›.
Kontrol grubu ratlar›n karaci¤er ve böbrek dokular›n›n histopatolojik incelenmesinde önemli de¤ifliklikler gözlenmedi (P > 0,05).
Diclofenac sodium tedavisi, karaci¤er ve böbrek dokular›n› önemli derecede etkiledi (P < 0,001). Diclofenac tedavili bütün gruplar›n,
hematoksilen-eosin ile boyal› karaci¤er kesitlerindeki histopatolojik de¤ifliklikler: Karaci¤er hücrelerinde bulan›k fliflkinlik ve hidropik
dejenerasyon, fokal sinüsoidal ve santral ven genifllemesi, portal alanlarda safra kanal proliferasyonu, mononükleer hücre
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infiltrasyonu ile birlikte periportal mesafe genifllemesi, hiperemi, fokal nekrozlar ve doza ba¤l› fibröz doku art›fl›yd›.
Diclofenac sodium tedavili bütün gruplar›n böbrek dokular›n›n tübüler epitel hücrelerinde bulan›k fliflkinlik ve hidropik dejenerasyon
görüldü. Fakat, nekroz, peritübüler lenfosit infiltrasyonu, interstisiyumda fibröz doku art›fl›, hiperemi ikinci ve üçüncü gruplarda
gözlendi. Yüksek doz diclofenac sodium verilen üçüncü grubun karaci¤er ve böbrek dokular›nda görülen nekroz, hidropik
dejenerasyon ve inflamasyon, düflük dozla karfl›laflt›r›ld›¤›nda, daha yayg›n ve yo¤un idi. Böbrek dokusunda ve karaci¤erin periportal
alanlar›nda düzensizli¤e neden olan ba¤ dokusu art›fl› sadece yüksek doz alan grupta görüldü. Bu bulgular, yüksek doz diclofenac
sodium’un karaci¤er ve böbrek dokular›nda anlaml› de¤iflikliklere neden oldu¤unu göstermektedir.
Anahtar Sözcükler: Diclofenac sodium, karaci¤er, böbrek, histopatolojik de¤ifliklikler

Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs),
which are often used for the relief of non-specific fever
(1), continue to be important for the palliation of pain
(2). They are the most frequently used medications for
the treatment of a variety of common chronic and acute
inflammatory conditions (3), and continue to be
important for the palliation of pain and in decreasing
inflammation and fever (4-7). Diclofenac sodium is a nonsteroidal anti-inflammatory agent (8). Diclofenac belongs
to a chemical subgroup of NSAIDs that are an arylalkanoic
group of phenylacetic acid (9) and advocated for use in
painful and inflammatory rheumatic and non-rheumatic
conditions (4-6). It may be used for the treatment of fetal
developmental problems and the prevention of premature
birth (5).
Diclofenac sodium has antipyretic, analgesic and antiinflammatory effects, is an inhibitor of cycloxigenase
enzyme and is decreased in leukocyte intracellular free
arachidonate level (10). The exact mechanism is not
known but it is probably related to the decrease in the
fatty acid entering the cell or released from the cell (10).
The literature has continued to broaden our
understanding of the potential toxic events associated
with the use of these agents (4-6).
Several studies have indicated that NSAIDs can
generally prevent prostaglandin synthesis from
arachidonic acid by inhibiting the activity of the
prostaglandin synthesizing enzyme, cyclooxygenase.
Prostaglandins are formed from dietary essential fatty
acids (principally arachidonic acid) esterified to
phospholipids and in some instances to trigliycerides.
These products have some potent biological activities
affecting cell function in every organ. The high levels of
NSAIDs also inhibit the activities of various enzymes, the
proteoglycan synthesis from chondrocytes, the ionic
1132

exchange rate and the processes depending on
prostaglandins (4-6).
Diclofenac is extremely metabolized in the liver (11).
Therefore, the present study aimed to investigate only
the hepatotoxic and nephrotoxic effects of increasing
doses of diclofenac on liver and kidney tissue in rats.

Materials and Methods
Forty albino adult male Wistar rats weighing 200 to
220 g were used in this study. They were divided into
four groups: a control group and three diclofenac groups,
each with 10 rats. The rats in the control group (n = 10)
were intramuscularly injected with physiologic saline (1 cc
per rat). The rats in the first (n = 10), second (n = 10)
and third diclofenac groups (n = 10) were intramuscularly
injected with 50, 100 and 150 mg/kg live weight/day
diclofenac sodium, respectively. The experiment lasted 5
days. Twenty-four hours after the last injections at the
end of 5 days, all the rats were cut under ether anesthesia
and tissue samples were taken from the liver and kidney.
Tissue samples were then fixed in a buffered formalin,
processed through graded alcohols and xylene, and
embedded in paraffin blocks. Tissue sections of 4-6 µ
were made at multiple levels. Sections were routinely
stained with hematoxylin and eosin and reticulum and
Masson’s trichrome. Mounted slides were examined and
photographed under a light microscope.
Changes in the experimental histopathologic
parameters for liver and kidney tissues were graded as
follows: (-) showing no changes, and (+) (++) and (+++)
indicating minimum, moderate and maximum changes,
respectively. These values were considered to be nonparametric, and therefore the data was statistically
analyzed by a Kruskal-Wallis test in order to determine
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the effects of all groups on each of the experimental
parameters, and a Mann-Whitney U test was used to
compare the means of each parameter between the
groups. A P value of < 0.05 was considered significant.
Findings
Histologic examination of the liver and kidney tissues
in the control group revealed no significant deviation
from the normal histological structures (Figs. 1 and 2).

The changes in the histologic structure of the liver and
kidney were significantly (P < 0.001) affected by the
first, second and third diclofenac sodium treatments
(Tables 1 and 2).
In the first diclofenac group although there were
mononuclear cell infiltrations, bile duct proliferation in
the periportal areas and minimal enlargement in the
periportal areas, sinusoidal and central vein dilatation

Figure 1.

Histologic appearance of rat liver from the control group. Normal lobular structure
is seen. Central vein (thin arrow) and hepatocytes (thick arrows) (Hematoxylineosin, x 48).

Figure 2.

Histologic section of rat kidney from the control group. Normal tubular (thin
arrow) and glomerular (thick arrow) structures are seen in the cortex
(Hematoxylin-eosin, x 120).
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Table 1. Histopathologic changes induced by different doses of diclofenac sodium in liver tissue.*
Control group
n = 10

First group
n = 10

Second group
n = 10

Third group
n = 10

P1

Hepatocyte degeneration

+

+

++

+++

< 0.001

Sinusoidal dilatation

+

+

++

+++

< 0.001

Central vein dilatation**

+

2

3

4-5

< 0.001

Enlargement of periportal area**

-

2

3

4

< 0.001

Bile duct proliferation**

-

2

3-4

4-5

< 0.001

Mononuclear cell infiltration

-

+

++

+++

< 0.001

Pleomorphism of the hepatocyte

-

-

+

+++

< 0.001

Conspicuous nucleolus

-

-

+

++

< 0.001

Hepatocyte with eosinophilic cytoplasma
and pyknotic nucleus

-

-

+

++

< 0.001

Parenchymal necrosis

-

-

+

++

< 0.001

Limiting plate irregularities

-

-

-

++

< 0.001

Increased fibrous tissue

-

-

-

+

< 0.001

1

The data was statistically analyzed by a Kruskal-Wallis test in order to determine the effects of all groups on each of the experimental parameters.
* Histopathologic assessments of the experimental parameters were graded as follows: (-) showing no changes and (+), (++) and (+++) indicating
mild, moderate and severe changes, respectively.
** The number of specified parameters was counted under the light microscope of 10 high power field.
n, number of observations.

Table 2. Histopathologic changes induced by different doses of diclofenac sodium in kidney tissue.*
Third group
n = 10

P1

Control group
n = 10

First group
n = 10

Second group
n = 10

Tubular epithelial cell degeneration

+

+

++

+++

< 0.001

Tubular epithelial cell necrosis

-

-

+

+++

< 0.001

Atrophic glomerulus and tubulus

-

-

-

++

< 0.001

Eosinophilic secretion in the tubulus lumen

-

-

+

++

< 0.001

Interstitial mononuclear cell infiltration

-

-

-

++

< 0.001

Increased fibrous tissue

-

-

+

++

< 0.001

Hyperemic vessels in the interstitium

+

+

++

+++

< 0.001

1

The data was statistically analyzed by a Kruskal-Wallis test in order to determine the effects of all groups on each of the experimental parameters.
* Histopathologic assessments of the experimental parameters were graded as follows: (-) showing no change and (+), (++) and (+++) indicating
mild, moderate and severe changes, respectively.
n, number of observations.

occurred in the liver tissues (Table 1); however, these
changes were not significantly (P > 0.05) different from
those observed in the control group (Table 3). In the
second diclofenac group we observed dilatation of the
central vein, sinusoidal dilatation around the central vein,
bile duct proliferation, enlargement of some portal areas
and cloudy swelling, parenchymal cell necrosis, mild
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pleomorphism and a conspicuous nucleolus in the
hepatocyte. Some hepatocytes have eosinophilic
cytoplasma and a pyknotic nucleus. Furthermore, there
was mononuclear cell infiltration in the periportal areas
(Table 1). Of the above changes, only bile duct
proliferation (P < 0.001), mononuclear cell infiltration (P
< 0.001) and parenchymal cell necrosis (P < 0.001) were
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Table 3. Statistical comparison for the differences between the experimental groups for liver parameters1.
Liver tissue

Control with
First group

Control with
Second group

Control with
Third group
> 0.05 (ns)

First group with
Second group

First group with
Third group

Second group with
Third group

Hepatocyte degeneration

> 0.05 (ns)

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Sinusoidal dilatation

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Central vein dilatation

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Enlargement of periportal area

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Bile duct proliferation

> 0.05 (ns)

< 0.001

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Mononuclear cell infiltration

> 0.05 (ns)

< 0.001

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Pleomorphism of the hepatocyte

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Conspicuous nucleolus

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Hepatocyte with eosinophilic
cytoplasma and pyknotic nucleus

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

> 0.05 (ns)

Parenchymal necrosis

> 0.05 (ns)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Limiting plate irregularities

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

Increased fibrous tissue

> 0.05 (ns)

> 0.05 (ns)

> 0.05

> 0.05 (ns)

> 0.05 (ns)

< 0.001
> 0.05 (ns)

1

Mann-Whitney U test was used to compare the means of each parameter between the groups.
ns: not significant

significantly different from those in the control group
(Table 3).
In the third diclofenac group the liver tissue samples
showed large widespread changes. The insignificant
histopathologic changes seen in the second diclofenac
group together with other parameters were significantly
(P < 0.001) different in the third diclofenac group
campared with the control group (Table 3). Additionally,
there were patchy parenchymal necrosis (P < 0.001),
limiting plate irregularities (P > 0.05), diffuse sinusoidal
dilatation (P < 0.001) and slightly increased fibrous
tissue (P > 0.05) as compared with the changes in the
control group (Figs. 3 and 4) (Table 3).
In the first diclofenac group kidney tissue samples
showed degenerative changes in the tubular epithelium
and hyperemic vessels in the cortical and medullar
interstitial areas (Table 2). However, these changes were
not significantly (P > 0.05) different from those in the
control group (Table 4). In the second diclofenac group
the changes observed compared with those in the first
diclofenac group were very common. In addition to focal
tubular epithelial degeneration and destruction (P <
0.001) there were mild fibrosis areas (P < 0.001), which
were stained with Masson’s trichrome in the interstitium
as compared with the control group (Tables 2 and 4).

In the third diclofenac group there were cortical and
medullar tubular epithelial degeneration (P < 0.001),
focal tubular epithelial necrosis (P < 0.001), some
atrophic glomerulus and tubulus (P < 0.001),
intratubular eosinophilic secretion (P < 0.001) and
increased fibrous tissue (P < 0.001) and mononuclear cell
infiltration in the interstitium (P < 0.001) as compared
with the control group (Tables 2 and 4) (Figs. 5 and 6).

Discussion
In the present study, dose-dependent changes were
seen in the liver tissue samples. In the first diclofenac
group, these changes were very mild and reversible.
Similar changes were also seen in the second diclofenac
group. In the third diclofenac group the changes seen
compared with those in the first diclofenac group were
aggressive and common: there were hepatocyte necrosis,
mild fibrous tissue proliferation and interstitial and
periportal inflammation, which indicate acute hepatitis.
These findings suggest that a high dose of diclofenac
sodium causes irreversible cell death, as well as cell
damage, fibrous tissue proliferation and acute hepatitis
(12,13). The association of NSAIDs with liver disease is
poorly documented. Reports on hepatic injury have
ranged from insignificant and transient liver enzyme
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Figure 3.

High dose diclofenac sodium administered group. Bile duct proliferation (star) in
portal area, enlargement in periportal area (thin arrow) with mononuclear cell
infiltration (thick arrow) and parenchymal cell degeneration (short arrows) are seen
(Hematoxylin-eosin, x 120).

Figure 4.

Higher magnification of liver lobule in high dose diclofenac sodium treated group.
Parenchymal cell necrosis (stars), sinusoidal dilatations (thin arrows), hepatocytes
with pyknotic nucleus and eosinophilic cytoplasma (thick arrows) are seen
(Hematoxylin-eosin, x 120).

elevation to severe and fulminant hepatitis (3). Diclofenac
sodium causes a rise in liver function, and has also been
reported to cause hepatitis (14-16). The hepatotoxic and
nephrotoxic effects of diclofenac sodium in both humans
and experimental animals have been reported (16-19).
1136

Nevertheless, the exact mechanism of the toxic effects
induced by diclofenac sodium has not yet been
determined (6). Diclofenac sodium is metabolized in liver
tissue and so is toxic to liver cells (11). The toxic effects
of diclofenac could be acute or reversible (6). Several
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Table 4. Statistical comparison for the differences between the experimental groups for kidney parameters1.
Kidney tissue

Control with
First group

Control with
Second group

Control with
Third group

First group with
Second group

First group with
Third group

Second group with
Third group

Tubular epithelial cell degeneration

> 0.05 (ns)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Tubular epithelial cell necrosis

> 0.05 (ns)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Atrophic glomerulus and tubulus

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

< 0.001

Eosinophilic secretion in the
tubulus lumen

> 0.05 (ns)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Interstitial mononuclear cell
infiltration

> 0.05 (ns)

> 0.05 (ns)

< 0.001

> 0.05 (ns)

< 0.001

< 0.001

Increased fibrous tissue

> 0.05 (ns)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Hyperemic vessels in the interstitium

> 0.05 (ns)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

1

Mann-Whitney U test was used to compare the means of each parameter between the groups.
ns: not significant

Figure 5.

Histologic section of rat kidney from the high dose administered group showing
degeneration (stars) and epithelial cell necrosis (thin arrows), in the epithelial lining
some of the tubules and mononuclear cell infiltration (thick arrow) in the
interstitium (Hematoxylin-eosin, x 120).

investigators have attempted to clarify the mechanism of
diclofenac-sodium-induced hepatotoxicity. It has been
reported that the damage in hepatocytes induced by
diclofenac sodium was associated with an idiosyncratic
reaction (14).
The effects of the anti-inflammatory drug diclofenac
on mitochondrial respiration, ATP synthesis and
membrane potential are known. These drugs stimulate
ATP synthesis and collapsed membrane potential in

mitochondria. Diclofenac blocks the activity of the
adenine nucleotide translocase and inhibits mitochondrial
ATPase activity (20). Diclofenac is more cytotoxic to drug
metabolizing cells than to non-metabolizing cell lines.
Despite the fact that diclofenac itself was effective in
impairing ATP synthesis by mitochondria, there was
evidence that toxicity was also related to the drug
metabolism and was reduced by the addition of
cytochrome p-450 inhibitors to the culture medium (21).
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Figure 6.

Histologic examination of rat kidney from high dose treated group showing
eosinophilic secretion in the tubulus lumen (stars) (Hematoxylin-eosin, x 120).

The non-steroidal anti-inflammatory drug diclofenac
causes a rare but potentially fatal hepatotoxicity that may
be associated with the formation of reactive metabolites
(22,23). These products presumably were formed via the
hepatic cytochrome P-450 (CYP)-catalyzed oxidation of
diclofenac to reactive benzoquinone imines that are
trapped by GSH (glutathione) conjugation. It is,
therefore, possible that reactive benzoquinone imines
may be formed and contribute to diclofenac-mediated
hepatic injury (24). Three metabolites of diclofenac
sodium are reported to be responsible for diclofenac
sodium toxicity in the liver, namely 4’ hydroxy 3
diclofenac, 5’ hydroxy 4 diclofenac and 5’ hydroxy 6
diclofenac (22,24). Some experimental results suggest
that the toxic effect of diclofenac on hepatocytes may be
caused by drug-induced mitochondrial impairment
together with a futile consumption of nicotinamide
adenine dinucleotide phosphate (NADPH) (21).
Mitochondrial damage and NADPH deficiency are thought
to be responsible for diclofenac sodium hepatotoxicity
(25).
We tested the effects of different doses of diclofenac
treatment in order to investigate histopathologic
differences between low and high doses. The present
histopathologic finding in the liver was in agreement with
diclofenac-sodium-induced hepatotoxicity that may
appear in acute or chronic liver disease. The hepatic
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changes we obtained were dose-dependent because we
observed meaningful histopathologic liver changes
accompanying with acute hepatitis and irreversible cell
changes with the use of high dose diclofenac compared to
low dose treatment.
The effects of NSAIDs in therapeutic doses on
oxidative stress have been established (23), but there is
little knowledge on the effects of high doses of these
drugs (26). The kidney is another organ affected by the
toxic effects of NSAIDs (27-29). It is known to be an
important target organ for the untoward effects of
NSAID, which can produce acute, reversible or permanent
effects (22,23,30-36). The toxic effects of diclofenac can
be acute or reversible (19). The NSAIDs adversely change
the kidney functions (10) and may play a role in the
induction of membranous nephropathy (37). During
diclofenac sodium metabolism the number of reactive
oxygen species can be increased. These products induced
prooxidative damage in renal tissue. The increase in SOD
levels (endogenous antioxidant enzymes) and MDA
activity (indicating lipid peroxidase) in renal tissue may
indicate peroxidative damage. In the renal tissue,
structural changes confirm oxidative changes including
reductions in GSH-Px and GR activities in the kidney and
increased MDA levels in serum. The decrease in GSH-Px
activity possibly destroys the process of H2O2 convertion
into H2O (12,13).
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Thus, an increased level of H2O2 can also cause cell
damage in kidney tissue (12). Diclofenac sodium causing
nephrotoxicity could be associated with the potent
inducer of the membrane permeability transition (MMPT)
in renal cortex mitochondria (19). MMPT increases
calcium uptake in mitochondria in the presence of reactive
oxygen species. The mitochondrial degeneration thus
occurs. This is associated with an increased level of intramitochondrial calcium in the renal tissue (38-42).
In the present study the high dose of diclofenac
caused tubular epithelial cell degeneration, and necrosis
that may be reversible or irreversible. With the low dose
of diclofenac sodium histopathologic changes in the
kidney tissue were reversible, but with the high dose
diclofenac these changes were common and irreversible
and there was also increased fibrous tissue in the
interstitial tissue of the kidney.
In a previous study, nephrotic syndrome (NS) was said
to be associated with NSAID use if the patient developed

NS while taking NSAID and if other causes of
membranous nephropathy were excluded, and a rapid
remission of the NS followed withdrawal of the drug
(37). It can be concluded that NS due to membranous
nephropathy should be recognized as an idiosyncratic
drug reaction to many NSAIDs (37).
In this experimental study there were significant
differences between the different doses of diclofenac. Dosedependent administration of diclofenac significantly altered
the histopathologic structure. The major histopathologic
events in the course of diclofenac cytotoxicity are
hepatocytes and renal tubule epithelial cell death, acute
hepatitis and moderate histopathologic changes that are
seen as in the case of chronic pyelonephritis.
In conclusion, pathologically liver injury associated
with NSAIDs is not prevalent but we think it is interesting
to report these results for the recognition of the
histopathologic events and disease in the course of
diclofenac cytotoxicity.
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